Ann: Update on Legal Proceedings and BARD1 Autoantibody Program, page-20

'...and subB2M had more promising prospects.'

Problem most of us probably have is there is little to no statistically-significant data/evidence that demonstrates the current unilateral Sub2M-direction is far outweighed by not running with both streams (BARD1 & Sub2M), my point, as far as I can tell in my research/reading, this 'undeniable' statistical-evidence is not present, leading me to believe it's more about the 'ego's' that came across with SDX, than the competition of alternative scientific approaches...

Is it was so compelling, why have we seen very little in the way of actually revenue/sales of any Sub2M product-line..??